A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Condition: Healthy Volunteers
Intervention: Deferiprone; Placebo
Intervention description: Deferiprone for infusion, 10mg/mL for intravenous infusion.
Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2); Placebo: normal saline solution.
Intervention MeSH terms: Deferiprone
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 64.0
Sex: All
Minimum age: 18 Years
Maximum age: 50 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Healthy; Deferiprone; DFP; L1

Summary:

      Single center, randomized, double-blind, placebo-controlled, adaptive sequential
      ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of
      single doses of deferiprone administered by intravenous infusion to healthy males and
      females. A bioavailability comparison will be included.
    

Eligibility criteria:

        Main Inclusion Criteria:

          1. Healthy adult males or females, at least 18 years old but not older than 50 years.

          2. Body weight at least 60kg.

          3. Body Mass Index (BMI) ≥ 18.50 and ≤ 30.00 kg/m2

          4. Medically healthy with clinically insignificant screening results (e.g., laboratory
             profiles, medical history, ECG, vital signs, physical examination.

          5. Non or ex-smoker (someone who has completely stopped smoking 6 months before study
             start)

          6. For females, negative result on a serum pregnancy test.

        Main Exclusion Criteria:

          1. Absolute neutrophil count (ANC) <1.5x10^9/L.

          2. History or presence of hypersensitivity to deferiprone or any related products.

          3. History or presence of gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs.

          4. Presence of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, endocrine, immunologic or dermatologic disease.

          5. Any history of tuberculosis (TB) or prophylaxis for TB.

          6. Suicidal tendency, history of seizures, head trauma with coma or
             craniotomy/trepanation, state of confusion or relevant psychiatric disease.

          7. Inadequate venous access in either arm.

          8. Presence of out-of-range cardiac interval or clinically significant ECG abnormalities
             (PR <110 msec or > 220 msec, QRS <60 msec or >119 msec, QTcB > 450 msec for males and
             >460 msec for females).

          9. Use of acetaminophen, acetylsalicylic acid (ASA), or non-steroidal anti-inflammatory
             drugs (NSAIDs) in the previous 7 days before study start.

         10. Use of any enzyme-modifying drugs, including strong inhibitors of P450 (CYP) enzymes
             such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole,
             ketoconazole, diltiazem, and HIV antivirals OR strong inducers of CYP enzymes such as:
             barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin, and St. John's wart
             within 28 days prior to study start.

         11. Maintenance therapy with any drug, or significant history of drug dependency or
             alcohol abuse.

         12. Had a clinically significant illness during the 28 days prior to study start.

         13. Receipt of an investigational product in another clinical trial within 28 days prior
             prior to study start.

         14. Enrolment in a previous cohort of this study.